ArticlePediatric pulmonology2025
Assessing the Impact of Nirsevimab Immunization on RSV Bronchiolitis Hospital Admissions and Their Severity: A Case-Control Study and Comparison With Pre- and Post-COVID-19 Seasons in a Tertiary Pediatric Hospital.
Article in Pediatric pulmonology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of COVID-19 on the epidemiological features of mycoplasma pneumoniae infection in children with community-acquired pneumonia in Ganzhou, China.Frontiers in immunology · 2026Article
- Longitudinal Analysis of Respiratory Syncytial Virus in Children during and after COVID-19 Pandemic in China: Shifts in Seasonality and Disease Burden.Journal of epidemiology and global health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionThis study evaluates nirsevimab's real-world effectiveness in preventing respiratory syncytial virus (RSV) bronchiolitis hospitalizations after its introduction in Andalusia's immunization schedule, compares clinical outcomes between immunized and non-immunized infants (2023-2024), and examines RSV seasonality pre- and post-COVID-19.
methodsRetrospective single-center case-control study conducted at a tertiary pediatric hospital (Malaga Regional University Hospital). Infants hospitalized for PCR-confirmed RSV bronchiolitis during the first season after nirsevimab introduction were matched with two controls born on the same day. Immunization status, demographic data, and clinical outcomes were analyzed. As a secondary analysis, clinical characteristics and adverse outcomes of immunized and non-immunized RSV bronchiolitis cases from the 2023-2024 season were compared with four previous periods: pre-pandemic decade (04/2010-03/2020), first pandemic season (04/2020-03/2021), second pandemic season (04/2021-03/2022) and third pandemic season (04/2022-03/2023).
resultsNirsevimab showed 91.5% effectiveness (95% CI: 71.8%-97.4%) in reducing RSV bronchiolitis hospitalizations, which decreased 72.4% from the pre-pandemic average and 82.4% from 04/2022-03/2023. Intensive-care-unit admissions were significantly higher in non-immunized infants (60.0% vs. 26.1%, p = 0.04), with no differences in bacterial superinfection, oxygen requirement and length-of-stay.
conclusionsNirsevimab significantly reduced RSV bronchiolitis hospitalizations during its first season of use. The study also highlights shifts in RSV seasonality trends influenced by the COVID-19 pandemic, highlighting the need for ongoing surveillance to adapt public health strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.